Valoración (Assay): Ensayo de unión a la diana que confirma la neutralización del factor regulado al alza en el adenocarcinoma pancreático (PAUF)
Purity: Anticuerpo monoclonal purificado que cumple con los estándares de pureza de grado biofarmacéutico
Perfil de impurezas: Proteínas de células hospedadoras, agregados e impurezas relacionadas con el proceso controladas dentro de los límites de especificación biofarmacéutica

Otra información

Descripción adicional:

Developed by Prestige Biopharma, PBP1510 (INN ulenistamab) is a first-in-class monoclonal antibody directed against pancreatic adenocarcinoma up-regulated factor (PAUF), a protein overexpressed in pancreatic adenocarcinoma that drives tumor growth, invasion, metastasis, immune evasion, and an immunosuppressive tumor microenvironment. By neutralizing PAUF, the antibody curbs its tumor-promoting effects in both cancer cells and the surrounding microenvironment. It holds Orphan Drug Designation from the FDA, EMA, and Korea's MFDS, plus FDA Fast Track status, and is in Phase 1/2a trials across the US, Europe, Asia, and Australia.